Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome

Blood (2016) 127 (26): 3387–3397.

https://doi.org/10.1182/blood-2016-02-699843

Published: 2016

Includes: Supplemental data

Journal Articles

Monocyte and Fibroblast Directed Generation of a Marrow Vascular Niche

Surya S Kotha, Kiet T Phong, Amie Adams, Brian Hayes, PhD, Meredith A Roberts, Karol Bomsztyk, MD, Aravind Ramakrishnan, MD, Beverly Torok-Storb, PhD, Ying Zheng, PhD

Blood (2015) 126 (23): 3602.

https://doi.org/10.1182/blood.V126.23.3602.3602

Published: 2015

Journal Articles

Low Efficacy and High Mortality Associated with Clofarabine Treatment of Patients with Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes

Daniel A Roberts, MD, Martha Wadleigh, MD, Anne McDonnell, PharmD, BCOP, Daniel J DeAngelo, Richard M. Stone, MD, David P. Steensma, MD

Blood (2014) 124 (21): 5282.

https://doi.org/10.1182/blood.V124.21.5282.5282

Published: 2014

Journal Articles

Codanin-1 mutations in congenital dyserythropoietic anemia type 1 affect HP1α localization in erythroblasts

Raffaele Renella, Nigel A. Roberts, Jill M. Brown, Marco De Gobbi, Louise E. Bird, Tasneem Hassanali, Jacqueline A. Sharpe, Jacqueline Sloane-Stanley, David J. P. Ferguson, Jacqueline Cordell, Veronica J. Buckle, Douglas R. Higgs, William G. Wood

Blood (2011) 117 (25): 6928–6938.

https://doi.org/10.1182/blood-2010-09-308478

Published: 2011

Includes: Supplemental data

Journal Articles

A Transgenic Mouse Model for Congenital Dyserythropoietic Anemia Type I

Raffaele Renella, MD, Nigel A Roberts, BSc, Jacqueline A Sharpe, PhD, Pik-Shan Li, BSc, Jill M Brown, BSc, Christian Babbs, PhD, Cristina Fugazza, PhD, Nicolas Goardon, PhD, Douglas R Higgs, DSc, William G Wood, PhD

Blood (2008) 112 (11): 3455.

https://doi.org/10.1182/blood.V112.11.3455.3455

Published: 2008

Journal Articles

Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.

Lisa M. Rimsza, MD, Michael L. LeBlanc, PhD, Robin A. Roberts, BS, Joseph M. Unger, MS, Thomas P. Miller, MD, Constantine M. Sabalos, MS, Ralph R. Martel, PhD, Elias Campo, MD, Andreas Rosenwald, MD, Joseph M. Connors, MD, Laurie H. Sehn, MD, Natalie Johnson, MD, Randy D. Gascoyne, MD

Blood (2007) 110 (11): 50.

https://doi.org/10.1182/blood.V110.11.50.50

Published: 2007

Journal Articles

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

Robin A. Roberts, BS, Lisa M. Rimsza, M.D., Louis Staudt, M.D.Ph.D., Andreas Rosenwald, M.D., Wing-Chung Chan, M.D., Sandeep Dave, M.D., Randy D. Gascoyne, M.D., Joseph M. Connors, M.D., Erlend B. Smeland, M.D.Ph.D., H.K. Muller-Hermelink, M.D., Elias Campo, M.D., Elaine S. Jaffe, M.D., Wyndham Wilson, M.D., Bruce K. Tan, M.D., Richard I. Fisher, M.D., Thomas M. Grogan, M.D., Thomas P. Miller, MD

Blood (2006) 108 (11): 809.

https://doi.org/10.1182/blood.V108.11.809.809

Published: 2006

Journal Articles

Loss of Major Histocompatibility Class II (MHCII) Gene Expression in Diffuse Large B Cell Lymphoma (DLBCL) Is Not Generally Due to Genetic Mutations in the Coding Regions of CIITA or RFX.

Robin A. Roberts, BS, Thomas P. Miller, M.D., Lisa M. Rimsza, MD

Blood (2006) 108 (11): 2039.

https://doi.org/10.1182/blood.V108.11.2039.2039

Published: 2006

Journal Articles

Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival

Robin A. Roberts, George Wright, Andreas R. Rosenwald, Marina A. Jaramillo, Thomas M. Grogan, Thomas P. Miller, Yvette Frutiger, Wing C. Chan, Randy D. Gascoyne, German Ott, H. Konrad Muller-Hermelink, Louis M. Staudt, Lisa M. Rimsza

Blood (2006) 108 (1): 311–318.

https://doi.org/10.1182/blood-2005-11-4742

Published: 2006

Journal Articles

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

Blood (2006) 107 (3): 1101–1107.

https://doi.org/10.1182/blood-2005-04-1510

Published: 2006

Journal Articles

Zoledronic Acid Plus Thalidomide Is Safe and Well Tolerated When Used as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Nonprogressive Multiple Myeloma.

Andrew Spencer, A. Roberts, T. Neeman, S. Cremers, H. Schran, K. Lynch

Blood (2005) 106 (11): 2551.

https://doi.org/10.1182/blood.V106.11.2551.2551

Published: 2005

Journal Articles

Defective Modification of Mannose Residues by Terminal Phosphoethanolamine Underlies Inherited GPI Deficiency.

A. M. Almeida, MD, P. Hillmen, MD, PhD, S. J. Richards, PhD, D. H. Crawford, PhD, A. Baker, MD, M. A. Ferguson, PhD, I. A. Roberts, MD, PhD, D. M. Layton, MD, PhD, A. Karadimitris, MD, PhD

Blood (2005) 106 (11): 128.

https://doi.org/10.1182/blood.V106.11.128.128

Published: 2005

Journal Articles

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Margaret E. Tome, David B. F. Johnson, Lisa M. Rimsza, Robin A. Roberts, Thomas M. Grogan, Thomas P. Miller, Larry W. Oberley, Margaret M. Briehl

Blood (2005) 106 (10): 3594–3601.

https://doi.org/10.1182/blood-2005-02-0487

Published: 2005

Journal Articles

Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.

Matthew W. Andres, DO, Robin A. Roberts, BS, Debbie J. Mustacich, PhD, Randy D. Gascoyne, MD, Deborah A. Fuchs, MD, Michael X. Wang, MD, Rita M. Braziel, MD, Wing C. Chan, MD, Thomas M. Grogan, MD, Lisa M. Rimsza, MD

Blood (2004) 104 (11): 4553.

https://doi.org/10.1182/blood.V104.11.4553.4553

Published: 2004

Journal Articles

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Lisa M. Rimsza, Robin A. Roberts, Thomas P. Miller, Joseph M. Unger, Michael LeBlanc, Rita M. Braziel, Dennis D. Weisenberger, Wing C. Chan, H. Konrad Muller-Hermelink, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Deborah A. Fuchs, Catherine M. Spier, Richard I. Fisher, Jan Delabie, Andreas Rosenwald, Louis M. Staudt, Thomas M. Grogan

Blood (2004) 103 (11): 4251–4258.

https://doi.org/10.1182/blood-2003-07-2365

Published: 2004

NARROW

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome

Monocyte and Fibroblast Directed Generation of a Marrow Vascular Niche

Low Efficacy and High Mortality Associated with Clofarabine Treatment of Patients with Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes

Codanin-1 mutations in congenital dyserythropoietic anemia type 1 affect HP1α localization in erythroblasts

A Transgenic Mouse Model for Congenital Dyserythropoietic Anemia Type I

Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

Loss of Major Histocompatibility Class II (MHCII) Gene Expression in Diffuse Large B Cell Lymphoma (DLBCL) Is Not Generally Due to Genetic Mutations in the Coding Regions of CIITA or RFX.

Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

Zoledronic Acid Plus Thalidomide Is Safe and Well Tolerated When Used as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Nonprogressive Multiple Myeloma.

Defective Modification of Mannose Residues by Terminal Phosphoethanolamine Underlies Inherited GPI Deficiency.

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only